Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has appointed Craig Boyd to the new leadership role of President, Xellia US.
Craig will be responsible for leading the growth of Xellia’s US business as the Company prepares to launch its pipeline of value-added anti-infective drug products into the US market. Xellia is also significantly expanding its commercial organisation with a new office planned in Chicago to complement its increased US manufacturing capabilities as its facilities in Cleveland Ohio come into full operation in 2018.
Craig brings more than 20 years’ experience in various global pharmaceutical markets, working extensively in the US, Asia, Europe and Australia and across numerous product categories such as brands, biosimilars, devices, generics and specialty generics. His most recent role was Chief Commercial Officer at Envigo. Previously he was the Executive Vice President of Mayne Pharma’s US specialty brands and prior to this Craig led global commercial sales functions at Hospira and Mylan. He also spent 10 years at Novartis as a senior commercial sales and marketing executive.
we will actively look to secure partnerships that will utilise the significant sterile injectable manufacturing footprint that Xellia is developing in the US."
Commenting on his appointment Boyd said: ”The US market is extremely important for Xellia and I am excited to be building the further growth of the Company’s business in this territory. As well as focusing on the new commercial business and product launches, we will actively look to secure partnerships that will utilise the significant sterile injectable manufacturing footprint that Xellia is developing in the US.”
Xellia’s pipeline of value-added anti-infectives drugs is centred on formulation improvements for marketed drugs from its core portfolio and is intended to enhance patient care. The most advanced product in Xellia’s pipeline is its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag, which was recently granted Qualified Infectious Disease Product (QIDP) designation from the U.S. Food & Drug Administration (FDA), providing incentives for the development of antibiotics, including priority review and eligibility for fast-track designation. During 2018, the Company plans to submit a New Drug Application (NDA) for this product to the FDA.
